methylphenidate hydrochloride: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
methylphenidate hydrochloride: clinical details
Prescribing considerations
- Initiation and supervision should be by a clinician with expertise in ADHD.
- Confirm a comprehensive diagnosis and functional impairment; medication forms part of psychological, educational and social management.
- Document cardiovascular and psychiatric history, concurrent medicines, substance-use risk and family history of sudden cardiac death before treatment.
- Choose the formulation according to required release profile, swallowing ability, food requirements and risk of misuse or diversion.
- Review ongoing benefit and tolerability; avoid abrupt withdrawal without clinical consideration.
Contraindications and cautions
- Hypersensitivity to methylphenidate or product excipients
- Current or recent monoamine oxidase inhibitor treatment
- Glaucoma or phaeochromocytoma
- Hyperthyroidism or thyrotoxicosis
- Specified severe or uncontrolled psychiatric disorders, including uncontrolled type I bipolar disorder
- Specified serious cardiovascular or cerebrovascular disease
Monitoring
- Blood pressure and pulse
- Height, weight and appetite in children; weight in adults
- New or worsening psychiatric symptoms, aggression, anxiety, psychosis, mania or suicidal thinking
- Tics or Tourette symptoms
- Seizure control where relevant
- Adherence, effectiveness, misuse and diversion
Clinical pharmacology
A racemic, indirectly sympathomimetic CNS stimulant. The more active d-enantiomer inhibits dopamine and noradrenaline transporters; methylphenidate is extensively metabolised, mainly to inactive ritalinic acid.
Formulation and product differences
- Immediate-release tablets provide a shorter release profile than modified- or prolonged-release products.
- Ambinet XL capsules use approximately equal immediate- and modified-release components and require food.
- Equasym XL and Tuzulby use an immediate-release component with a larger extended-release component.
- Xaggitin XL prolonged-release tablets must remain intact.
- Tuzulby is chewable; selected capsule products may be opened and sprinkled, but their contents must not be chewed.
- Modified-release brands are not automatically interchangeable because release profiles and food instructions differ.
methylphenidate hydrochloride preparations and strengths
Capsule
Route: Oral
Strengths: 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg
methylphenidate hydrochloride interactions
Tell the prescriber and pharmacist about all medicines, supplements and planned surgery.
Monoamine oxidase inhibitors
Combined use, or recent MAOI use, is contraindicated because of the risk of a hypertensive crisis.
Antihypertensives
Methylphenidate may reduce their blood-pressure-lowering effect.
Medicines that raise blood pressure
Combined use may further increase blood pressure and requires caution and monitoring.
Coumarin anticoagulants
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.